These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10638007)

  • 1. [Treatment of visceral leishmaniasis in patients with antimonials: is there a maximal dose?].
    Llorens Soriano P; Vicente Ull R; Paricio Blasco A; Cervera Juan A; Rubio Rodrigo MJ
    An Med Interna; 1999 Nov; 16(11):602. PubMed ID: 10638007
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pancreatic toxicity of antimonials in patients with infections].
    Sánchez LA; Ferrero OL; Zubero Z; Teira R; Muñoz J; Baraia-Etxaburu J; Santamaría JM
    Rev Esp Enferm Dig; 2000 Nov; 92(11):765-6. PubMed ID: 11468860
    [No Abstract]   [Full Text] [Related]  

  • 3. The irreplaceable image: Acute toxicity in erythroid bone marrow progenitors after antimonial therapy.
    Hernández JA; Navarro JT; Force L
    Haematologica; 2001 Dec; 86(12):1319. PubMed ID: 11726328
    [No Abstract]   [Full Text] [Related]  

  • 4. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Santos J; Rivero A; Márquez M
    An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
    Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
    Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
    [No Abstract]   [Full Text] [Related]  

  • 8. Visceral Leishmaniasis in children in the Yemen.
    Haidar NA; Diab AB; El-Sheik AM
    Saudi Med J; 2001 Jun; 22(6):516-9. PubMed ID: 11426243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful therapeutic splenectomy in an HIV patient with relapsing visceral leishmaniasis.
    Alon D; Chowers M
    Int J STD AIDS; 2012 Apr; 23(4):289-90. PubMed ID: 22581957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
    Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of HIV infection in resistant cases of Indian kala-azar.
    Jha TK; Singh NK; Thakur CP; Singh TK
    J Assoc Physicians India; 1994 Mar; 42(3):263. PubMed ID: 7860533
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of visceral leishmaniasis using sodium stibogluconate in a dose of 15 mg antimony/kg body weight twice daily for 30 days: a preliminary report.
    Chunge CN; Gachihi G; Mugambi M; Chulay JD; Spencer HC
    East Afr Med J; 1984 Jul; 61(7):570-4. PubMed ID: 6100588
    [No Abstract]   [Full Text] [Related]  

  • 13. [Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection].
    Cortés E; Ribera E; Cucurull E; de Otero J; Ocaña I; Pahissa A
    Med Clin (Barc); 1995 Apr; 104(15):578-80. PubMed ID: 7769868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Visceral leishmaniasis in a renal transplant recipient: diagnostic and therapeutic problems.
    Sharma RK; Jha R; Kumar P; Kher V; Gupta A; Kumar A; Gulati S; Arora P; Murari M; Bhandari M
    Am J Nephrol; 1996; 16(4):358-60. PubMed ID: 8739293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical risk factors for therapeutic failure in kala-azar patients treated with pentavalent antimonials in Nepal.
    Rijal S; Bhandari S; Koirala S; Singh R; Khanal B; Loutan L; Dujardin JC; Boelaert M; Chappuis F
    Trans R Soc Trop Med Hyg; 2010 Mar; 104(3):225-9. PubMed ID: 19726065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis].
    Laguna del Estal P; Calabrese S; Zabala JA; Martín T
    Med Clin (Barc); 1994 Feb; 102(7):276-7. PubMed ID: 8170219
    [No Abstract]   [Full Text] [Related]  

  • 17. Visceral leishmaniasis presenting as generalized lymphadenopathy in Nepal.
    Sah SP; Raj GA; Kalra OP; Ansari JA
    Southeast Asian J Trop Med Public Health; 1999 Mar; 30(1):36-7. PubMed ID: 10695785
    [No Abstract]   [Full Text] [Related]  

  • 18. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection.
    Gilad J; Borer A; Hallel-Halevy D; Riesenberg K; Alkan M; Schlaeffer F
    Isr Med Assoc J; 2001 Jun; 3(6):451-2. PubMed ID: 11433642
    [No Abstract]   [Full Text] [Related]  

  • 19. Does antimony therapy cause bleeding in kala-azar patients and why?
    Chowdhury MA; Ahasan HA; Azhar MA; Rafiqueuddin AK; Islam MR; Misbahuddin M; Rashid MU
    Trop Doct; 1995 Oct; 25(4):188-9. PubMed ID: 7502336
    [No Abstract]   [Full Text] [Related]  

  • 20. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.